Bridgeport Hospital is a not-for-profit general medical and surgical hospital in Bridgeport, Connecticut. It is a member of Yale New Haven Health System and affiliated with Yale School of Medicine. During 2018, Bridgeport Hospital received professional recognition for geriatric and palliative care, diabetes treatment, human rights and local economic partnership.
Background Metabolic dysfunction-associated steatotic liver disease (MASLD) affects approximately one-quarter of adults worldwide, yet liver fibrosis remains markedly under-recognized in primary care. Existing screening approaches using static risk calculators yield single numeric outputs without explanation, actionable recommendations, or supporting documentation, limiting their adoption and clinical impact. Methods We developed FibroAgent, a conversational agentic AI framework that integrates a validated machine-learning XGBoost-based prediction model, patient-specific explainability via SHapley Additive exPlanations (SHAP), risk-stratified clinical pathways, an interactive educational knowledge base, and structured documentation within a single autonomous agent. FibroAgent was designed following established agentic AI principles: proactiveness, autonomy, reactivity, and transparency, and requires only seven routinely available clinical parameters (age, glycated hemoglobin (HbA1c), alanine aminotransferase (ALT), aspartate aminotransferase (AST), platelet count, body mass index (BMI), and glomerular filtration rate (GFR)). We demonstrated its capabilities across low-risk, intermediate-risk, and high-risk patient scenarios, batch screening of a six-patient cohort, and error-handling validation. Results FibroAgent correctly stratified patients with advanced liver fibrosis into rule-out (probability <=0.20), indeterminate (0.20-0.69), and rule-in (>=0.70) categories with corresponding risk-appropriate clinical recommendations. SHAP-based explanations identified platelet count, AST, and age as the top-three risk contributors in high-risk patients, providing a clinically interpretable rationale for each prediction. The agent demonstrated robust error handling, maintaining analytical continuity despite simulated tool failures. Conclusions FibroAgent represents a novel and promising approach to transitioning from static fibrosis calculators to interactive, explainable, and autonomous clinical decision support. By unifying prediction, explanation, recommendation, education, and documentation within a single conversational agent, FibroAgent offers a scalable, imaging-independent triage solution for primary care and resource-limited settings.
Peripheral neuropathies encompass a broad spectrum of disorders, such as traumatic, compressive, inflammatory, metabolic, and neoplastic, that collectively affect millions of individuals in the United States. Their clinical presentations often overlap leading to diagnostic challenges. While electrodiagnostic studies help differentiate axonal from demyelinating processes and aid in assessing muscle reinnervation, they provide limited information regarding lesion localization, extent, and spatial distribution. MRI and ultrasonography offer complementary structural assessment, though US is constrained by lower sensitivity for deep nerves, operator dependence, and challenges in detecting subtle fascicular or muscle changes. Magnetic Resonance Neurography (MRN) has emerged as a transformative, non-invasive imaging technique that enables high-resolution visualization of peripheral nerves, plexuses, and associated pathologies. Leveraging advanced hardware, superior fat and vascular signal suppression, 3D isotropic acquisitions, and nerve-selective sequences, MRN overcomes the limitations of conventional MRI and allows detailed evaluation of fascicular architecture and denervation patterns. This first article in a two-part series reviews the technical foundations of MRN, including hardware considerations, sequence selection, and optimization strategies essential for high-quality nerve imaging. It also introduces NS-RADS, a standardized reporting and scoring system designed to enhance consistency and diagnostic confidence. The companion article focuses on clinical applications, characteristic and key imaging features, and pathognomonic MRN signs across common and uncommon neuropathies.